Literature DB >> 2250598

Endothelin-induced vasoconstriction of small resistance vessels in the microcirculation of the rat cremaster muscle.

I G Joshua1.   

Abstract

Recently, a peptide (endothelin) which has been shown to have potent vasoconstrictor properties has been isolated from the vascular endothelium. In the present study, we assessed the responsiveness of small arterioles and venules in the rat cremaster muscle to topical application of endothelin using closed-circuit television microscopy. Exposure to increasing concentrations of endothelin (10(-15)-10(-7) M) produced a dose-dependent constriction in large (90 +/- 8 microns), intermediate (50 +/- 6 microns), and small (21 +/- 4) arterioles. Large (144 +/- 17 microns) and intermediate (79 +/- 18 microns) venules also constricted to the peptide, but the responses were inconsistent and smaller in magnitude. The constriction to endothelin was long lasting and resistant to washout. Arteriolar reactivity to endothelin was similar for all vessel levels with ED50 values ranging from 10(-9) to 10-s;1(0) M. Exposure to the calcium entry blocker, verapamil, attenuated the endothelin-induced constriction in 3A arterioles, suggesting that the constriction in skeletal muscle arterioles is at least partially due to the increased entry of extracellular calcium.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2250598     DOI: 10.1016/0026-2862(90)90018-m

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  2 in total

1.  Haemodynamic effects of endothelin receptor antagonist, tezosentan, in tumour necrosis factor-alpha treated anaesthetized rats.

Authors:  Reza Tabrizchi; Carol Ann Ford
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-18       Impact factor: 3.000

2.  Effects of endothelin receptor antagonists on bradykinin-induced increases in macromolecular efflux.

Authors:  W G Mayhan; I Rubinstein
Journal:  Inflammation       Date:  1994-12       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.